Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fenretinamide in preparation of medicine for treating or preventing viral hepatitis

A viral hepatitis, the use of technology, applied in the field of antiviral drugs, to achieve good druggability, excellent clinical safety, the effect of removing hepatitis B virus

Pending Publication Date: 2022-07-01
HOLY HAID LAB CORP
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The current research on the indications of fenretinide mainly focuses on its application in the treatment or prevention of tumors and other diseases, and there is no research report on its use in the treatment or prevention of viral hepatitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fenretinamide in preparation of medicine for treating or preventing viral hepatitis
  • Application of fenretinamide in preparation of medicine for treating or preventing viral hepatitis
  • Application of fenretinamide in preparation of medicine for treating or preventing viral hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Example 1 - Evaluation of the in vitro anti-HBV activity of the test compound fenretinide using HepG2-NTCP cells

[0069] The compound preparation method is as follows:

[0070] Taking the preparation of 10mM concentration as an example, the volume of solvent DMSO (μl) = sample mass (mg) × purity ÷ molecular weight ÷ 10 × 10 6

[0071] Control compounds included ETV (lot number: P1214012; 99.0% purity), purchased from Shanghai Titan Technology Co., Ltd.; and RG7834 (RG7834, also known as RO 7020322, a highly selective and orally bioavailable HBV inhibitor with potent Inhibits HBV antigens (HBsAg and HBeAg) and HBV DNA. Lot number: ET25747-14-P1; 99.5% purity), obtained from Shanghai WuXi AppTec New Drug Development Co., Ltd. The stock concentrations of the above control compounds were all 20 mM and stored at -20°C.

[0072] Table 1: Main reagents and cellular viruses

[0073]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of fenviretin A in preparation of a medicine for treating or preventing viral hepatitis. Specifically, the invention provides application of a compound 1, a derivative of the compound 1 or pharmaceutically acceptable salt of the compound 1 in preparation of drugs for treating or preventing viral hepatitis, and preferably, the viral hepatitis is hepatitis B. The invention also provides a pharmaceutical composition for treating or preventing viral hepatitis, which comprises compound 1 or a pharmaceutically acceptable salt thereof and optionally one or more additional therapeutic or prophylactic agents, as well as a pharmaceutically acceptable carrier.

Description

technical field [0001] The present invention relates to the technical field of antiviral drugs, in particular, to a pharmaceutical composition for treating or preventing viral hepatitis and its application. Background technique [0002] Human hepatitis B virus (HBV) infection is a major public health problem worldwide. After acute hepatitis B virus infection, about 8% still develop chronic hepatitis B infection, and persistent HBV infection will lead to liver cirrhosis and even liver cancer. my country is a big country with hepatitis B, with nearly 130 million hepatitis B virus carriers, accounting for about 9% of the total population. Although with the widespread popularization of hepatitis B vaccine, the infection rate of new hepatitis B has been effectively controlled, but the population base of hepatitis B carriers is large, and prevention and treatment of hepatitis B has become the top priority of my country's public health problems. HBV transmission is mainly through...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/167A61K45/06A61P31/20
CPCA61K31/167A61K45/06A61P31/20
Inventor 李瑛颖陈明键仇思念
Owner HOLY HAID LAB CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com